Elixir licenses anti-aging enzyme patent from BU

By Mass High Tech Staff

Synta starts trials of new anti-cancer drug [March 17, 2009]

Synta cancer trial failure has major downstream effects [March 13, 2009]

Epix takes in $500K more for cystic fibrosis research [March 11, 2009]

Synta postpones 10-K filing, conference call [March 11, 2009]

Elixir Pharmaceuticals Inc. reports it has reached an exclusive license agreement with Boston University in relation to patents that cover compounds that modulate a gene linked to an anti-aging enzyme known as a sirtuin.

The licensing deal expands the Cambridge biotech firm’s intellectual property holdings related to sirtuins, which have gained tremendous attention for their role in metabolic functions and the aging process.

Cambridge drug developer Sirtris Pharmaceuticals, another firm focused on sirtuins, was acquired by British drug giant GlaxoSmithKline PLC in June for $720 million.

Privately held Elixir says it is conducting pre-clinical research of compounds that modulate genes related to sirtuins for the treatment of Type 2 diabetes, obesity, Huntington’s disease and certain types of cancer. The company has rights to 20 issued and pending patents concerning sirtuins.

In May, Elixir cancelled an $86.3 million initial public offering. The firm’s local venture capital investors include MPM Capital and Oxford Bioscience Partners, both of Boston.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.